TOPS System
Phase 3- Indications
- Spinal stenosis, Spondylolisthesis
Company intelligence / Profile preview
Premia Spine develops innovative spinal implants for minimally invasive procedures. Its flagship product, the TOPS™ System—a lumbar facet joint replacement—has demonstrated clinical superiority over lumbar fusion for treating degenerative spondylolisthesis and spinal stenosis. In a pivotal FDA trial with over two years of follow-up, the TOPS device showed a significantly higher overall clinical success rate compared to fusion (77% vs. 24%). The system preserves mobility post-decompression and offers an alternative to traditional fusion surgery. The company has also developed ProMIS™ and Nexux™ systems.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Premia Spine.